TileBio, a spin-out from the University of Glasgow, has raised £1.6M in seed funding led by Twin Path Ventures to develop AI technology for cancer diagnosis.
TileBio has secured £1.6M in seed investment to launch AI technology focused on cancer diagnosis and treatment. The funding will support AI model training, clinical validation studies, and team expansion. Investors include Twin Path Ventures, Scottish Enterprise, and GU Holdings Ltd. The aim is to create one of the largest pathology foundation models globally using real-world clinical data.
Who to call at TileBio, and when
A new round usually means TileBio is about to hire and buy. The teams that reach out first get the meeting.
An alert the day TileBio raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at TileBio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at TileBio. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
TileBio
Location
Glasgow, Scotland, United Kingdom
About
TileBio is a spin-out company from the University of Glasgow focused on developing AI technology to improve cancer diagnosis and treatment. The company has created a platform that enables AI systems to learn from millions of unlabelled medical pathology images, enhancing the speed and accuracy of diagnoses. With a long-term goal of creating one of the largest pathology foundation models globally, TileBio leverages large-scale clinical data to drive innovation in medical AI.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment TileBio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
GlasgowBiotechnologyHealth CareArtificial IntelligenceMedicalMachine LearningHealth Diagnostics